It will become one of the first countries to roll out the new malaria vaccine, R21, after receiving a first batch of 846,200 ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

CIDRAP reports that federal health officials know of 90 cases of Oropouche virus from five states, mostly from Florida, although none of the cases is known to have been sexually transmitted. Plus: ...

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Dow, S&P 500, and Nasdaq futures are rising in premarket trading Thursday as the stock market reacts to Taiwan Semiconductor earnings in light of the recent ASML selloff.